Cpx-351
Myelodysplastic Syndrome With Excess Blasts
Explore 32 assets in Myelodysplastic Syndrome With Excess Blasts →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Ohio State University Comprehensive Cancer Center
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04049539CT.gov Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | — | Recruiting | — | — | — |
NCT04128748CT.gov Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome With Excess Blasts
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cpx-351 (this asset) | Ohio State University Comprehensive Cancer Center | P1/2 | CCC · 48 |
| Cytarabine | University of Southern California | P3 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | BB |
| Fludarabine | Fred Hutchinson Cancer Center | P3 | BB |
| Idarubicin | Fred Hutchinson Cancer Center | P3 | BB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Dexasone | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Myelodysplastic Syndrome With Excess Blasts cohort
Other indications for Cpx-351
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome | — | P2 | BB · 67 |
| Myelodysplastic Syndrome | — | P2/3 | B · 63 |
| Acute Myeloid Leukemia | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cpx-351 in Myelodysplastic Syndrome With Excess Blasts. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cpx-351-myelodysplastic-syndrome-with-excess-blasts
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →